Home › Funds › Elmind Capital, LP › DBVT

Elmind Capital, LP position in DBVT

DBV TECHNOLOGIES S A · Health Care

Elmind Capital, LP reported holding 265,000 shares of DBVT (DBV TECHNOLOGIES S A) in its Q2 2026 13F filing — a position valued at US$4.3M, representing 1.09% of its reported portfolio and ranking #23 among its reported holdings. Elmind Capital, LP has disclosed DBVT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)265.00K sh
Reported value held$4.35M
Portfolio Weight1.09%
First reportedQ1 2026
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Elmind Capital, LP's DBVT position evolved

Elmind Capital, LP first disclosed a stake in DBVT in Q1 2026 at 265,000 shares (US$5.5M). Across 2 filings, Elmind Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 265,000 shares valued at US$4.3M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 265.00K $5.54M New
Q2 2026 265.00K $4.35M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DBVT and 13F data

DBVT (DBV TECHNOLOGIES S A) is a Health Care company. 57 other funds we track also report a position in DBVT — the largest reported positions include MPM BioImpact LLC (US$60.1M), Siren, L.L.C. (US$30.5M), Vivo Capital, LLC (US$30.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DBVT

All DBVT fund holders →

FAQ

How long has Elmind Capital, LP held DBVT?

Elmind Capital, LP has disclosed DBVT holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Elmind Capital, LP's current position in DBVT?

As of Q2 2026, Elmind Capital, LP holds 265.00K shares of DBVT (DBV TECHNOLOGIES S A), valued at $4.35M, representing 1.09% of its reported portfolio and ranking #23.

Has Elmind Capital, LP been buying or selling DBVT?

In the latest 13F filing (Q2 2026), Elmind Capital, LP held unchanged its position in DBVT.

Which other funds hold DBVT?

Other major institutional holders of DBVT include MPM BioImpact LLC, Siren, L.L.C., Vivo Capital, LLC, among 57 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.